Prime Medicine, Inc.
PRMEPrime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
28dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PM359 | Phase 2 | Chronic Granulomatous Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Prime Medicine, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Prime Medicine, Inc.'s (PRME) pipeline across Phase 2. Its lead program is PM359 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Prime Medicine, Inc.'s next FDA catalyst?→
Prime Medicine, Inc.'s (PRME) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PRME biotech catalysts?→
Add PRME to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Prime Medicine, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.